Published in Arch Ophthalmol on May 01, 1967
THE BLOOD FLOW, VASCULAR RESISTANCE, AND OXYGEN CONSUMPTION OF THE BRAIN IN ESSENTIAL HYPERTENSION. J Clin Invest (1948) 3.95
Interpretation of tear film breakup. Arch Ophthalmol (1977) 1.56
Visual fields in diabetic retinopathy. Br J Ophthalmol (1971) 1.15
Clinical experience with nucleosides in herpes simplex eye infections in man and animals. Ann N Y Acad Sci (1965) 1.09
Intraocular penetration of cephaloridine in humans. Am J Ophthalmol (1968) 1.05
Histocompatibility (HL-A) antigens and primary open-angle glaucoma. Tissue Antigens (1976) 1.05
Serratia marcescens, an ocular pathogen; new considerations. Arch Ophthalmol (1971) 1.04
The incidence of uveitis in multiple sclerosis. Am J Ophthalmol (1966) 1.04
Marginal (ring) corneal ulcer as presenting manifestation of Wegener's granuloma. A clinicopathologic study. Trans Am Acad Ophthalmol Otolaryngol (1971) 1.01
The role of lymphocyte (cell-mediated) immunity in ocular disease. The fifth Frederick H. Verhoeff lecture. Am J Ophthalmol (1973) 1.01
Ocular pigmentation and pressure and outflow responses to pilocarpine and epinephrine. Am J Ophthalmol (1971) 1.00
A clinical evaluation of the effects of topically applied levobunolol and timolol on increased intraocular pressure. Am J Ophthalmol (1982) 0.96
The potential use of quinolones in future ocular antimicrobial therapy. Am J Ophthalmol (1988) 0.95
Oral isosorbide and intraocular pressure. Am J Ophthalmol (1970) 0.92
Inhibition of leucocyte migration by corneal antigen in chronic viral keratitis. Nat New Biol (1971) 0.92
Clinical evaluation of the Humphrey automatic refractor. Arch Ophthalmol (1984) 0.91
Intraocular penetration of cephalexin in man. Am J Ophthalmol (1970) 0.90
Topical hetrazan in the treatment of ocular onchocerciasis. Am J Ophthalmol (1970) 0.90
Use of flurbiprofen to inhibit corneal neovascularization. Arch Ophthalmol (1980) 0.90
Cellular immunity in chronic ophthalmic disorders. 3. Leukocyte migration inhibition in uveitis. Am J Ophthalmol (1972) 0.89
New dimensions in ocular pharmacology. XXII Edward Jackson Memorial Lecture. Am J Ophthalmol (1966) 0.88
Clinical immunology in ophthalmology. The 1975 Bedell lecture. Am J Ophthalmol (1976) 0.88
Zinc deficiency and visual impairment? Am J Ophthalmol (1978) 0.87
The use of aceclydine in the treatment of glaucoma. Its effect on intraocular pressure and facility of aqueous humor outflow as compared to that of pilocarpine. Am J Ophthalmol (1967) 0.87
Treatment of uveitis with methotrexate. Am J Ophthalmol (1969) 0.86
Mycobacterium fortuitum infection of corneal graft. Arch Ophthalmol (1969) 0.86
Topical diethylcarbamazine in the treatment of ocular onchocerciasis. Am J Trop Med Hyg (1970) 0.85
Cellular immunity in chronic ophthalmic disorders. 2. Leukocyte migration inhibition in diseases of the cornea. Am J Ophthalmol (1972) 0.84
Leucocyte-migration inhibition induced by uveoretinal antigen in patients with diabetic retinopathy. Diabetes (1976) 0.83
Ocular penetration of hetrazan in rabbits. Am J Ophthalmol (1968) 0.83
Effect of hyperbaric oxygenation on microcirculation: use in therapy of retinal vascular disorders. Invest Ophthalmol (1965) 0.83
Intraocular penetration of sodium cephalothin in man after subconjunctival injection. Am J Ophthalmol (1972) 0.83
Intraocular penetration of carbenicillin after subconjunctival injection in man. Am J Ophthalmol (1972) 0.83
Trends in ocular therapy. Am J Ophthalmol (1968) 0.82
The phenylephrine saga--a drug dilemma. Am J Ophthalmol (1978) 0.82
Human cellular immunity to lens leukocyte migration inhibition by lens protein. Arch Intern Med (1974) 0.81
Angiotensin-converting enzyme activity in ocular fluids. Invest Ophthalmol Vis Sci (1981) 0.81
Leukocyte migration inhibition in chronic ophthalmic disorders. 5. Diabetic retinopathy and the effect of photocoagulation. Am J Ophthalmol (1973) 0.81
Herellea vaginicola and ocular infections. Ann Ophthalmol (1975) 0.81
Editorial: The importance of HL-A antigens in ophthalmology. Am J Ophthalmol (1975) 0.81
Noncorticosteroidal anti-inflammatory agents in Ophthalmology. Ophthalmology (1979) 0.81
Four common ocular complications of diabetes--and how to treat them. Geriatrics (1978) 0.80
Management of intra-ocular infection. Trans Ophthalmol Soc U K (1971) 0.80
Intraocular penetrating of amoxicillin. Am J Ophthalmol (1976) 0.80
Antiproteolytic activities found in human tears. Ophthalmology (1981) 0.80
Plasma zinc levels in multiple sclerosis. Metab Pediatr Ophthalmol (1980) 0.80
Resistance of rabbits and guinea pigs to the diabetogenic effect of streptozotocin. Diabetes (1969) 0.80
Excretion of salicylic acid into tears following oral administration of aspirin. Ophthalmology (1980) 0.79
Influence of topically applied prazosin on the intraocular pressure of experimental animals. Arch Ophthalmol (1979) 0.79
Advances in ocular corticosteroid therapy. Med Clin North Am (1973) 0.79
Calcium in tears and contact lens wear. Arch Ophthalmol (1980) 0.79
Intestinal absorption of dietary fat in patients with multiple sclerosis. Metab Pediatr Syst Ophthalmol (1985) (1993) 0.79
Advances in ocular therapy: noncorticosteroid anti-inflammatory agents. Fifth annual Jules Stein Lecture. Am J Ophthalmol (1974) 0.78
Forskolin, a potent adenylate cyclase activator, lowers rabbit intraocular pressure. Arch Ophthalmol (1984) 0.78
Advances in anesthesia in ophthalmic surgery. Ophthalmic Surg (1974) 0.77
Studies on serum pseudocholinesterase in glaucoma. Am J Ophthalmol (1966) 0.77
Cholinesterase isoenzymes in rabbit ocular tissue homogenates. Doc Ophthalmol (1969) 0.77
Topically applied oxymetazoline. Ocular vasoconstrictive activity, pharmacokinetics, and metabolism. Arch Ophthalmol (1983) 0.77
Intraocular penetration of cefazolin sodium in rabbits. Am J Ophthalmol (1974) 0.77
Hereditary optic atrophy. An autosomal dominant with incomplete penetrance. Arch Ophthalmol (1969) 0.77
The blood-aqueous and blood-brain barriers to permeability. Am J Ophthalmol (1988) 0.76
Calcium and protein in tears: diurnal variation. Arch Ophthalmol (1981) 0.76
Studies on plasma cholinesterase isoenzymes in glaucoma. Am J Ophthalmol (1968) 0.76
Retinopathy in Rocky Mountain spotted fever. Am J Ophthalmol (1969) 0.76
Cellular immunity in chronic ophthalmic disorders. I. Lymphocyte stimulation and protein synthesis. Am J Ophthalmol (1972) 0.76
The influence of systemic drugs on tear constituents. Ophthalmology (1979) 0.76
Aqueous humor, cerebrospinal fluid, and atriopeptin. Am J Ophthalmol (1987) 0.76
Leukocyte migration inhibition in chorioretinitis. Infect Immun (1974) 0.75
Ophthalmology-Epitomes of Progress: HLA Antigens and Glaucoma. West J Med (1979) 0.75
The fifth Frederick H. Verhoeff Lecture. The role of the lymphocyte (cell-mediated) immunity in ocular disease. Trans Am Ophthalmol Soc (1973) 0.75
The multiple-choice question test of the American Board of Ophthalmology. Trans Am Ophthalmol Soc (1970) 0.75
Hyperbaric oxygenation and corneal neovascularization in the rabbit. Am J Ophthalmol (1968) 0.75
New antifungal therapy in ophthalmology. Trans Am Ophthalmol Soc (1973) 0.75
As I remember: Francis Heed Adler. Eye Ear Nose Throat Mon (1975) 0.75
Cholinergic and anticholinesterase agents in glaucoma therapy. Trans Pac Coast Otoophthalmol Soc Annu Meet (1965) 0.75
Diethylcarbamazine and uveitis. Isr J Med Sci (1970) 0.75
Thoughts on pharmacologic research. J Am Intraocul Implant Soc (1981) 0.75
Intraocular penetration of topical clindamycin in rabbits. II. Clindamycin phosphate. Arch Ophthalmol (1978) 0.75
POB programming and diabetes. Sight Sav Rev (1975) 0.75
Ocular effects in normal rabbits of topically applied labetalol: a combined alpha- and beta-adrenergic antagonist. Arch Ophthalmol (1979) 0.75
Considerations of clinical immunology in ocular disease. Trans Pac Coast Otoophthalmol Soc Annu Meet (1977) 0.75
Intraocular penetration of topically applied lincomycin hydrochloride in rabbits. Arch Ophthalmol (1979) 0.75
New dimensions in ocular pharmacology. Trans Am Acad Ophthalmol Otolaryngol (1967) 0.75
Ocular examinations in outpatients given long-term chlorpromazine therapy. JAMA (1966) 0.75
Prices, patients and drug substitution. Am J Ophthalmol (1978) 0.75
Rabbit lens uptake of tritium-labelled phospholine iodide. Am J Ophthalmol (1969) 0.75
Immunotherapy and ocular malignancy. Am J Ophthalmol (1976) 0.75
A. Edward Maumenee all-American ophthalmologist. Am J Ophthalmol (1979) 0.75
Editorial: Bioavailability, bioequivalence and bias. Am J Ophthalmol (1975) 0.75
Ocular hypotensive action of labetalol. Am J Ophthalmol (1979) 0.75
Glaucoma masque. Am J Ophthalmol (1967) 0.75
Intraocular penetration of methicillin. Am J Ophthalmol (1965) 0.75
Steroids in ophthalmology. Bibl Ophthalmol (1967) 0.75
The HLA system and glaucoma. Am J Ophthalmol (1979) 0.75
A symposium on glaucoma. Research, use of research findings, and physician-patient relationships for successful treatment. Sight Sav Rev (1966) 0.75
Ocular complications of drugs. Visual changes. JAMA (1968) 0.75
Cholinesterases and the effects and side-effects of drugs affecting cholinergic systems. Am J Ophthalmol (1966) 0.75
How ophthalmic drugs can fool you. RN (1980) 0.75
New dimensions in ocular pharmacology 1975. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol (1976) 0.75
The steroid shield in ophthalmology. Trans Am Acad Ophthalmol Otolaryngol (1967) 0.75